U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06803875) titled 'Study of HALK.CAR T Cells for Patients with Relapsed/refractory High-risk Neuroblastoma' on Sept. 16, 2024.
Brief Summary: This Phase 1/2 trial aims to determine the safety and feasibility of administration of autologous chimeric antigen receptor (CAR) T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor in pediatric subjects with relapsed or refractory neuroblastoma (NB).
The trial will be conducted in two phases:
Phase 1 will determine the maximum tolerated dose (MTD) of autologous hALK.CAR T cells using a 3+3 dose escalation design. Phase 2 will be an expansion phase to determine rates of response to hALK.CAR T ...